Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.38M Buy
43,109
+7,272
+20% +$394K 0.12% 154
2025
Q4
$1.76M Buy
35,837
+5,251
+17% +$245K 0.09% 174
2025
Q3
$1.32M Buy
30,586
+3,256
+12% +$127K 0.07% 203
2025
Q2
$1.05M Buy
27,330
+5,700
+26% +$218K 0.06% 219
2025
Q1
$838K Sell
21,630
-1,208
-5% -$44.2K 0.05% 231
2024
Q4
$772K Buy
22,838
+2,508
+12% +$90.3K 0.05% 239
2024
Q3
$831K Buy
20,330
+6,708
+49% +$274K 0.05% 228
2024
Q2
$524K Buy
+13,622
New +$573K 0.04% 260

Other funds holding GSK

Foster & Motley's GSK Position: Q1 2026 in Review

Foster & Motley increased its GSK (GSK) stake by 20% in Q1 2026, buying an estimated $394K and bringing the position to 43,109 shares worth $2.38M. The position accounts for 0.12% of the portfolio, ranked #154.

Foster & Motley first reported a position in GSK in Q2 2024 and has held it in 8 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Foster & Motley held 43,109 shares of GSK worth $2.38M as of Q1 2026.
  • Foster & Motley bought 7,272 GSK shares in Q1 2026, an estimated $394K.
  • GSK made up 0.12% of Foster & Motley's portfolio in Q1 2026, its #154 holding.
  • Foster & Motley first reported a position in GSK in Q2 2024 and has held it in 8 quarters since.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Foster & Motley's 13F filing for Q1 2026, filed 21 Apr 2026.